Treatment of Pulmonary DS-TB in Patients with HIV Infection
Drug-sensitive pulmonary tuberculosis presenting alongside HIV infection requires a carefully coordinated treatment strategy. The presence of HIV influences both regimen selection and the timing of additional therapy, making this clinical scenario distinct from TB treatment in immunocompetent patients.
Clinical Scenario
Pulmonary drug-sensitive TB (DS-TB) with concurrent HIV infection. TB patients living with HIV should receive at least the same duration of TB treatment as HIV-negative patients.
Treatment Approach
Management involves a rifampicin-containing anti-TB regimen, with regimen selection informed by the patient's immune status, combined with early initiation of antiretroviral therapy — the full protocol specifies the preferred regimen, timing, and immune-status thresholds that guide clinical decision-making.
Treatment Goals
The primary endpoints are conversion of the sputum culture to negative and improvement of TB symptoms.
References
- It is recommended that TB patients who are living with HIV should receive at least the same duration of TB treatment as HIV-negative TB patients.
- There is much experience of treating these patients with the 6-month rifampicin-containing regimen 2HRZE/4HR.
- Although all three regimens (Table 1.2.1) can be initiated in PLHIV, the 6-month regimen is a preferred option in those with a CD4 count of less than 100 cells/mm3.
- Antiretroviral therapy (ART) should be started as soon as possible within 2 weeks of initiating TB treatment, regardless of CD4 cell count, among people living with HIV.
- For pulmonary DS-TB, the most important evidence of improvement is conversion of the sputum culture to negative.
View source ↗